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Rosai–Dorfman disease (RDD) is a proliferative histiocytic disorder of unknown etiology,
which is characterized by sinus histiocytosis with massive lymphadenopathy (1). In most
cases, RDD has a benign course and treatment is not necessary. However, severe cases
of RDD require treatment, and the treatment strategy is determined on the basis of the
severity of the disease or the extranodal involvement of vital organs. We report a single
case of RDD with atypical presentation of persistent constitutional symptoms, progress-
ing pathologic fractures, and end-organ dysfunction, including acute kidney failure and liver
cirrhosis with esophageal varices.
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A 55-year-old African American woman presented with a
10-month history of night sweats, fever, weight loss, and
hepatosplenomegaly. The patient had experienced an episode of
transient renal failure requiring 2 weeks of dialysis 3 months before
presentation. Her initial physical exam was significant for no
palpable lymphadenopathy.
Positron emission tomography/computed tomography at
presentation showed 18F fluorodeoxyglucose-avid right car-
diophrenic, periportal, left gastric, and peripancreatic lym-
phadenopathy with a maximum node diameter of 3.5 cm and a
maximum standard uptake value of 5.0; hepatosplenomegaly with
craniocaudal dimensions of 22 and 14 cm for the liver and spleen,
respectively; and non-displaced rib fractures at right sixth and
seventh ribs.
Excisional biopsy of a right axillary lymph node revealed reac-
tive lymph node changes characterized primarily by mantle zone
and marginal zone hyperplasia with few small residual germinal
centers. Multiple small non-necrotizing granulomas were identi-
fied. Sinuses were reactive and contained unremarkable sinus his-
tiocytes without discernible emperipolesis. Immunohistochem-
istry showed B-cell predominance with minimal paracortical
expansion.
Bone marrow biopsy demonstrated that 40–50% of cellularity
with trilineage hematopoiesis. There was no morphologic
evidence of infiltration by leukemia, lymphoma, or other
malignancy.
Liver biopsy showed established cirrhosis, perisinusoidal fibro-
sis with prominent proliferation of bile ductal cells, and mild
inflammation (predominantly small lymphocytes with a few
plasma cells). Esophagogastroduodenoscopy revealed esophageal
varices and small varices in the gastric fundus.
Eight months after presentation, the patient developed patho-
logic fracture of the left ischium. Positron emission tomogra-
phy/computed tomography showed a lytic lesion involving the
left inferior pubic ramus with a soft tissue component measuring
2.5 cm× 1.8 cm and an associated non-displaced cortical frac-
ture of the left inferior pubic ramus at the site of the lytic lesion
(Figure 1).
Surgical biopsy of the left ischium revealed a mixed inflamma-
tory infiltrate composed of large histiocytes, lymphocytes, and
plasma cells. The histiocytes demonstrated emperipolesis and
were reactive for both CD163 and S-100 proteins; consistent with
Rosai–Dorfman disease (RDD) (Figure 2).
The patient was given single-agent cladribine, 5 mg/m2, for
days 1 through 5 in 28-day cycles. After five cycles of single-
agent cladribine, magnetic resonance imaging confirmed com-
plete resolution of the soft tissue mass in the pubic ramus
and a well-healed pathologic fracture. Repeat positron emission
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FIGURE 1 | Positron emission tomography/computed tomography of
the pelvis showed a hypermetabolic lytic lesion with a pathologic
fracture involving the left inferior pubic ramus with maximum SUV
15.1 associated with a soft tissue mass 2.5 cm.×1.8 cm.
FIGURE 2 | Left ischium biopsy. (A) Collections of histiocytes admixed
with lymphocytes are seen involving bone (H&E, 100×). (B) High power
reveals the histiocytes demonstrate emperipolesis, engulfing lymphocytes
(H&E, 400×). Immunohistochemical studies reveal that the histiocytes
co-express (C) CD163 and (D) S-100 protein.
tomography/computed tomography showed residual multicom-
partmental adenopathy and demonstrated no visible 18F fluo-
rodeoxyglucose uptake.
In our patient, the surgical biopsy of the left ischium demon-
strated histiocyte emperipolesis and CD163 and S-100 protein
expression. The presence of emperipolesis by histiocytes, which
are positive for S-100 and CD163, is diagnostic of RDD (2–4).
Our patient’s clinical presentation was atypical because of liver
cirrhosis, kidney involvement, and confirmed pathologic frac-
tures. The most frequent clinical presentation of RDD is massive
bilateral, painless cervical lymphadenopathy with constitutional
symptoms including fever, night sweats, and weight loss (5).
Skeletal lesions of RDD are typically osteolytic and can be
confused radiographically with Langerhans cell histiocytosis (5).
Extranodal involvement is commonly observed in the upper res-
piratory tract, skin, and soft tissue and less commonly observed
in cases with thyroid, kidney, and skeletal involvement including
spine (5–9).
18F fludeoxyglucose positron emission tomography can detect
the metabolically highly active lesions of RDD (10). RDD often
takes a self-limited benign course with frequent incidence of spon-
taneous resolution; nevertheless, approximately 10% of patients
die of RDD due to the extranodal involvement in multiple
sites and the progressive proliferation or relapse of systemic
lymphadenopathy over several years (11).
In our patient, the persistent constitutional symptoms, progres-
sive pathologic fractures, and end-organ dysfunction – including
a previous episode of kidney failure requiring dialysis and liver
cirrhosis with esophageal varices – justified further intervention.
Results with chemotherapeutic agents have not been encour-
aging, although case reports or case series have demonstrated
clinical benefits or responses in patients with RDD treated with
cladribine (12–15). In our patient, treatment with five cycles
of cladribine resulted in radiographic improvement and stable
lymphadenopathy without 18F fluorodeoxyglucose uptake.
In conclusion, the use of chemotherapy should be restricted
to patients whose disease is life-threatening, does not respond
to conservative treatments, or relapses multiple times after other
treatments since RDD is self-limited in most patients. We report a
single case of RDD in which treatment with single-agent cladribine
resulted in symptom improvement.
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